Moreover, the involvement of CCR2 and CCR5 has been shown in preclinical models of obesity-induced hypersensitivity and diabetic neuropathy, where administration of dual CCR2/CCR5 antagonists led to pain reduction [204]. Here, CCR5 is linked to obesity disorder.